SanBio, Inc.

Founded in February 2001 SanBio's scope of business is development, production and sales of regenerative cell medicines. Our mission is to develop regenerative medicines, creating benefits for patients and value for stakeholders. Our vision is to achieve global leadership in the regenerative medicine field using best science and technology, building global revenues and sponsoring successful clinical trials. SanBio focuses on using regenerative cell medicine to treat the disabilies caused by diseases of the central nervous system. Most of these conditions currently have no effective medicinal treatment, and those treatment that do exist generally address disease symptoms and not the underlying cause of the disease. Such conditions afflict a vast number of patients worldwide.As of January, 2016, SanBio had introduced a product for the treatment of chronic motor impairment from ischemic stroke and traumatic brain injury into clinical development in both Japan and the US. In the future, SanBio plans to continue expanding the indications and geographical regions for its products, using both internal development, as well as partnerships and licenses.